Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jonathan J. Hue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1608-8874; OpenAlex author ID A5052355726. Sources: OpenAlex.

Their work

Papers
25 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2020: 1 paper · 2021: 6 papers · 2022: 9 papers · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 25

  1. A ketogenic diet sensitizes pancreatic cancer to glutamine metabolism inhibitors. Co-author DOI 10.1016/j.xcrm.2026.102770↗
  2. A Word of Caution: Operation Alone Remains Inadequate for Pancreatic Cancer. Co-author DOI 10.1097/xcs.0000000000001735↗
  3. Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies. Co-author DOI 10.1158/2767-9764.crc-25-0338↗
  4. Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Co-author DOI 10.18632/oncotarget.28739↗
  5. IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-1895↗
  6. To Revise or Not Revise? Isolated Margin Positivity in Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15616-y↗
  7. An analysis of time to treatment in patients with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.03.011↗
  8. Increased glucose availability sensitizes pancreatic cancer to chemotherapy. First author DOI 10.1038/s41467-023-38921-8↗
  9. Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study. First author DOI 10.1245/s10434-023-14221-9↗
  10. Prodromal depression and anxiety are associated with worse treatment compliance and survival among patients with pancreatic cancer. First author DOI 10.1002/pon.5945↗
  11. Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. Co-author DOI 10.1016/j.amjsurg.2021.10.001↗
  12. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreati… First author DOI 10.1016/j.hpb.2021.08.938↗
  13. Multimodal therapy with or without irreversible electroporation for unresectable locally advanced pancreatic adenocarcinoma: a systematic review and meta-analy… Co-author DOI 10.1016/j.hpb.2021.12.014↗
  14. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2022.07.007↗
  15. Time to Neoadjuvant Chemotherapy Initiation Is not Associated With Survival in Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2022.03.013↗
  16. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Co-author DOI 10.1016/j.surg.2021.10.023↗
  17. Surgical techniques and tips for a reliable murine model of primary and metastatic pancreatic cancer Co-author DOI 10.1101/2022.07.30.502136↗
  18. IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression. Co-author DOI 10.1158/1535-7163.mct-22-0055↗
  19. The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis. First author DOI 10.1002/cnr2.1390↗
  20. Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.11.035↗
  21. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodene… Co-author DOI 10.1016/j.surg.2020.12.003↗
  22. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1089/pancan.2021.0003↗
  23. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagen… Co-author DOI 10.1177/00031348211038581↗
  24. ASO Author Reflections: Prediagnosis Weight Loss: Early Detection and Postoperative Prognosis Among Patients with Pancreatic Cancer Co-author DOI 10.1245/s10434-021-09894-z↗
  25. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? First author DOI 10.18632/oncotarget.27727↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan Michael Winter · 23 shared papers, 2020–2026 · strength 3.69
  2. Luke Daniel Rothermel · 15 shared papers, 2021–2026 · strength 2.29
  3. John Brian Ammori · 15 shared papers, 2020–2024 · strength 2.27
  4. Jeffrey M. Hardacre · 15 shared papers, 2020–2024 · strength 2.27
  5. Lee Mayer Ocuin · 14 shared papers, 2020–2024 · strength 2.11
  6. Kavin Sugumar · 12 shared papers, 2021–2025 · strength 1.88
  7. Ali Vaziri Gohar · 7 shared papers, 2022–2026 · strength 1.19
  8. Mehrdad Zarei · 7 shared papers, 2022–2026 · strength 1.19
  9. Omid Hajihassani · 7 shared papers, 2022–2026 · strength 1.19
  10. Mohamedraed Elshami · 6 shared papers, 2022–2024 · strength 0.96
  11. Erryk Katayama · 6 shared papers, 2020–2026 · strength 0.95
  12. Sarah Coseo Markt · 5 shared papers, 2021–2022 · strength 0.78
  13. David Lawrence Bajor · 5 shared papers, 2020–2022 · strength 0.66
  14. Jonathan Robert Brody · 3 shared papers, 2023–2026 · strength 0.54
  15. Matthew H. G. Katz · 1 shared paper, 2026 · strength 0.50
  16. Rebecca Anne Snyder · 1 shared paper, 2026 · strength 0.50
  17. Shreya Gupta · 2 shared papers, 2023 · strength 0.36
  18. Moeez Ghani Rathore · 2 shared papers, 2023–2026 · strength 0.32
  19. Jennifer Anne Dorth · 2 shared papers, 2021–2022 · strength 0.26
  20. Lisa M. Coussens · 1 shared paper, 2026 · strength 0.23
  21. Katie E. Blise · 1 shared paper, 2026 · strength 0.23
  22. Sami O. Abul-Khoudoud · 1 shared paper, 2026 · strength 0.23
  23. Robert L Eil · 1 shared paper, 2026 · strength 0.23
  24. Rosalie C. Sears · 1 shared paper, 2026 · strength 0.23
  25. Charles D. Lopez · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.